Dr. Garmey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 College Rd E
G P C Biotech
Princeton, NJ 08540Phone+1 609-936-3100
Education & Training
Icahn School of Medicine at Mount SinaiClass of 2001
Certifications & Licensure
NY State Medical License 2005 - 2019
Clinical Trials
- CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) Start of enrollment: 2014 Jul 01
Publications & Presentations
PubMed
- 70 citationsPhase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.Jonathan W. Goldman, Isett Laux, Feng Chai, Ronald E. Savage, Dora Ferrari
Cancer. 2012-12-01 - 325 citationsRandomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung CancerLecia V. Sequist, Joachim von Pawel, Edward Graeme Garmey, Wallace Akerley, Wolfram Brugger
Journal of Clinical Oncology. 2011-08-20 - 9 citationsVoluntary counseling and testing among post-partum women in BotswanaIbou Thior, Lesego Gabaitiri, Janet M. Grimes, Roger L. Shapiro, Shahin Lockman
Patient Education and Counseling. 2007-03-01
Press Mentions
Chutes & Ladders—Novartis Brings in New CEO to Clean up Korean BranchAugust 24th, 2018- Sensei Brings on New CMO as It Eyes Phase 2 Immuno-Oncology TrialAugust 21st, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
